ITEM 2. Management’s Discussion and Analysis of
Financial Condition and Results of Operations
Overview
The Company was originally incorporated on April 23, 2002 in
Minnesota as BioDrain Medical, Inc. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to
an Agreement and Plan of Merger effective December 16, 2013, the Company merged with and into a Delaware corporation with the same
name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On August
31, 2015, the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On February 1, 2018,
we filed with the Secretary of State of Delaware a Certificate of Amendment to our Certificate of Incorporation to change our corporate
name from Skyline Medical Inc. to Precision Therapeutics Inc., effective February 1, 2018. Because of this change, our common stock
trades under the new ticker symbol “AIPT,” effective February 2, 2018.
We are a healthcare products and services company that is expanding
its business to take advantage of emerging areas of the dynamic healthcare market through sales of its products, through its partnership
with Helomics Holding Corporation (“Helomics”) a pioneering Contract Research Organization (“CRO”) Services
company and through pursuit of other strategic relationships to build value. In our STREAMWAY business, we manufacture an environmentally-conscious
system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care.
Since our inception in 2002, we have invested significant resources into product development. We believe that our success
depends upon converting the traditional process of collecting and disposing of infectious fluids from the operating rooms of medical
facilities to our wall-mounted Fluid Management System (“System”) and use of our proprietary cleaning solution and
bifurcated filter. We have acquired 25% of the capital stock of Helomics, and on June 28, 2018, we entered into a definitive merger
agreement for a proposed merger transaction to acquire the remaining ownership of Helomics. See “Merger Agreement with Helomics”
below. In addition, we have formed a wholly-owned subsidiary, TumorGenesis Inc., to develop the next generation, patient derived
tumor models for precision cancer therapy and drug development.
We currently have a Vice President of Sales, one in house sales person, five regional
sales managers, and a Vice President of International Sales to sell the STREAMWAY System. In the third quarter we hired two additional
regional sales managers representing the Company in the United States. We have hired a regional sales representative in the quarter
ended March 31, 2018 to sell the STREAMWAY in Germany. We have also hired 3 independent contractors to further represent the Company
in certain regions of the United States. We have contracted with two General Purchasing Organizations in the United States,
Vizient and Intalere, providing customer exposure to more than 10,000 hospitals. The Company has contracted with Alliant Enterprises,
LLC, a Service Disabled Veterans Owned Small Business supplier to the federal government. We have executed contracts with three
international distributors. Quadromed, a Canadian distributor will represent us throughout Canada over the next two years, with
annual automatic renewals. MediBridge Sarl, a Swiss distributor will represent us in Switzerland over the next two years, with
annual automatic renewals. Device Technologies Australia PTY LTD, an Australian distributor will represent us throughout Australia,
New Zealand, Fiji and the Pacific Islands over the next five years with annual automatic renewals.
Since inception, we have been unprofitable. We incurred net
losses of approximately $2.4 million and $4.1 million for the three and six months ended June 30, 2018, and $2.5 million and $3.9
million for the three and six months ended June 30, 2017, respectively. As of June 30, 2018, and June 30, 2017, we had an accumulated
deficit of approximately $58.9 million and $50.9 million, respectively. We received approval from the FDA in April 2009 to commence
sales and marketing activities of the STREAMWAY System and shipped the first system in 2009. However, there was no significant
revenue prior to 2011, primarily due to lack of funds to build and ship the product.
In the first quarter of 2014, the Company commenced sales of
an updated version of the STREAMWAY System, which provide a number of enhancements to the existing product line including a more
intuitive and easier to navigate control screen, data storage capabilities, and additional inlet ports on the filters, among other
improvements. This updated version utilizes improved technology, including the capability for continuous flow and continuous suctioning,
as covered by our provisional patent application filed in 2013 and our non-provisional patent application filed in January 2014.
We have sold one hundred thirty-two STREAMWAY units through June 2018 and have since sold another two units for a total of one
hundred thirty-four units to date.
In making sales of STREAMWAY System units, we often utilize
trial-based units. Trial basis units are either installed in or hung on the hospital room wall. The unit is connected to the hospital
plumbing and sewer systems, as well as, the hospital vacuum system. The unit remains on the customer site for 2 – 4 weeks,
as contracted, at no cost to the customer. However, the customer does purchase the disposable kits necessary to effectively operate
the units. Once the trial period has expired the unit is either returned to the Company or purchased by the customer. If purchased,
at that time, the Company invoices the customer based upon a contracted price negotiated prior to the trial.
We have never generated sufficient revenues to fund our capital
requirements. We have funded our operations through a variety of debt and equity instruments. See “Liquidity and Capital
Resources – Liquidity, Plan of Financing and Going Concern Qualification” and “Liquidity and Capital Resources
– Financing Transactions” below.
Our future cash requirements and the adequacy of available funds
depend on our ability to sell our products and the availability of future financing to fulfill our business plans. We have committed
significant capital and management resources to developing our contract research organization (“CRO”) business and
other new business areas, including advancing $668,000 to Helomics and $1,070,000 to CytoBioscience. In addition, we have increased
our expenditures to develop the business of our TumorGenesis subsidiary, to pursue a new rapid approach to growing tumors in the
laboratory. It is likely that we will make further investments and advances in other businesses as we develop our CRO business
and other business models. Upon completion of the Helomics merger, we expect that our operating cash needs will increase significantly.
See “Plan of Financing; Going Concern Qualification” below.
As a company, our limited history of operations makes prediction
of future operating results difficult. We believe that period to period comparisons of our operating results should not be relied
on as predictive of our future results.
Merger Agreement with Helomics
On June 28, 2018, the Company entered into an Agreement and Plan
of Merger (the “Merger Agreement”) with Helomics and certain other entities. The Merger (as defined below) will provide
the Company with full access to Helomics’ suite of Artificial Intelligence (AI), precision diagnostic and integrated CRO
capabilities, which improve patient care and advance the development of innovative clinical products and technologies for the treatment
of cancers. Helomics’ precision oncology services are based on its D-CHIP diagnostic platform, which combines a database
of genomic and drug response profiles from over 149,000 tumors with an AI based searchable bioinformatics platform. The Merger
Agreement contemplates a reverse triangular merger with Helomics surviving the merger with Merger Sub and becoming a wholly-owned
operating subsidiary of the Company (the “Merger”). At the time of the Merger, all outstanding shares of Helomics stock
not already held by the Company will be converted into the right to receive a proportionate share of 7.5 million shares of newly
issued common stock in the Company (“Merger Shares”), in addition to the 1.1 million shares of the Company’s
common stock already issued to Helomics for the Company’s initial 20% ownership in Helomics. Additionally, 860,000 shares
of the merger consideration are to be held in escrow for 18 months to satisfy indemnification claims. Helomics’ management
team is expected to remain in their respective leadership positions at Helomics and to manage the existing TumorGenesis operations.
Helomics currently has outstanding $7.6 million in promissory notes and warrants to purchase
18.7 million shares at an exercise price of $1.00 per share of Helomics common stock held by the investors in the notes. As a result
of the Merger, the holders of said promissory notes and warrants will be entitled to additional warrants to purchase up to 5 million
additional shares of Helomics common stock at an exercise price of $1.00 per share. Helomics agrees to use commercially reasonable
efforts to cause the holder of each such promissory note to enter into an agreement whereby such holder agrees that, effective
upon the closing of the Merger, (a) all or a certain portion of the indebtedness evidenced by such promissory note shall be converted
into common stock in the Company, (b) all of such holder’s Helomics’ warrants shall be converted into warrants of the
Company, and (c) the unconverted portion of said indebtedness shall be converted into a promissory note issued by the Company dated
as of the closing of the Merger. The Merger is expressly conditioned on the holders of at least 75% of the $7.6 million in outstanding
Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged
for a Company warrant at a ratio of 0.6 Precision warrants for each Helomics warrant, with an exercise price of $1.00 per share.
If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an
aggregate estimated 23.7 million shares of the Company’s common stock and warrants to purchase an additional 14.2 million
shares of the Company’s common stock at $1.00 per share. The common stock issuable upon exercise of the Company warrants
will be registered in connection with the Merger. In addition, Helomics currently has 995,000 warrants held by other parties at
an exercise price of $0.01 per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the
time of the closing of the Merger for warrants to purchase 597,000 shares of the Company’s common stock at $0.01 per share.
The Merger Agreement also obligates the Company to approve, prior to the closing of the Merger, the grant of stock options exercisable
for an aggregate of 900,000 shares of common stock in the Company under the Company’s existing equity plan to the employees
and consultants of Helomics designated by Helomics, according to the allocation determined by Helomics in good faith consultation
with the Company.
Completion of the Merger is also subject
to (i) customary closing conditions including the approval of the Merger by the stockholders of both companies, (ii) certain materiality-based
exceptions, (iii) the accuracy of the representations and warranties made by, and the compliance or performance of the obligations
of, each of the Company and Helomics set forth in the Merger Agreement, (iv) satisfactory results of the Company’s due diligence
of Helomics, and (v) satisfactory results of Helomics’ due diligence of the Company. The Merger Agreement likewise contains
customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue
to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information.
Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics.
Minority Investment in Helomics
On January 11, 2018, the Company engaged in a share exchange transaction
with Helomics in which the Company acquired beneficial ownership of 20% of Helomics’ outstanding stock. On February 27, 2018,
the Company exchanged $500,000 in promissory notes of Helomics for an addition 5% of Helomics’ stock. As a result, the Company
is required to record net income or loss to investee, based on a percentage of the net income or loss equal to the Company’s
percentage ownership.
Helomics experienced a net loss from continuing operations of $4,285,054, for the six-month
period ended June 30, 2018. As a result, the Company recorded net loss to the Company of $960,508 for the six-month period ended
June 30, 2018. Helomics’ net loss included a one-time expense of $1,153,998 related to the conversion of non-interest bearing
convertible notes payable for non-convertible notes that bear interest and additional warrants. The remainder of Helomics’
loss is due to a reduction of revenue by reserving a substantial amount of third party revenue from insurance companies on diagnostic
income. The second half of the year is expected to include CRO and D-CHIP revenues that are expected to increase Helomics’
revenues and reduce losses. Helomics is a development stage company that may experience losses in future periods that will result
in net loss to investor. Due to the Company’s minority investment, such Helomics’ losses may have a material adverse
effect on the Company’s financial position and results of operations for such future periods.
Results of Operations
Revenue.
|
|
Three Months Ended June 30,
|
|
|
|
|
|
Six Months Ended June 30,
|
|
|
|
|
|
|
2018
|
|
2017
|
|
$ Difference
|
|
% Difference
|
|
2018
|
|
2017
|
|
$ Difference
|
|
% Difference
|
|
Revenue
|
|
|
$
|
358,586
|
|
|
$
|
106,822
|
|
|
$
|
251,764
|
|
|
|
236
|
%
|
|
$
|
770,179
|
|
|
$
|
281,988
|
|
|
$
|
488,191
|
|
|
|
173
|
%
|
There were 25 sales of STREAMWAY units in the in the six months
ended June 30, 2018, compared to 3 sales of STREAMWAY units in the comparable 2017 period. We expect that our strategy of hiring
additional sales representatives will have a greater revenue effect in the future quarters.
Cost of sales.
Cost of sales was $109,000 in the three
months ended June 30, 2018 and $22,000 in the three months ended June 30, 2017. Cost of sales was $226,000 in the six months ended
June 30, 2018 and $59,000 in the six months ended June 30, 2018. The gross profit margin was approximately 71% in the six months
ended June 30, 2018, compared to 79% in the prior year. Our margins were reduced in 2018 due to higher costs. Eventually, we expect
increased sales to allow us to achieve volume purchasing discounts on both equipment components and our cleaning solution, which
we expect to improve our margins.
General and Administrative expense.
General and administrative
expense primarily consists of management salaries, professional fees, consulting fees, travel expense, administrative fees and
general office expenses.
General and Administrative (G&A) expenses decreased by $1,485,000 for the three months
ended June 30, 2018 compared to the 2017 period. The decrease in the three-month period is primarily from investors stock compensation
$1,662,000 in the 2017 period due to our registered direct offering in November 2016 with warrants that vested in 2017, and for
amendments to stock options in 2017; and from consulting expenses in 2017, including $220,000 paid by issuing shares of stock to
a consulting firm to assist in sales, placements, company acquisitions, and hiring product distributors. Offsets in 2018 were from
an increase in stock based compensation due to vesting expense for employees, $209,000; increases in investor relations expenses,
$75,000 due to hiring additional analysts and investor relations firms; increases in legal fees toward merger and acquisition activity,
$42,000; increases in audit and accounting fees due to engaging a new audit firm, $49,000; and, an increase in personnel recruiting
fees, $19,000.
General & Administrative expenses decreased by $1,401,000 for the six months ended
June 30, 2018 compared to the 2017 period. The decrease in the six-month period is primarily from investors stock compensation
$2,150,000 in the 2017 period due to our registered direct offering in November 2016 with warrants that vested in 2017, and for
amendments to stock options in 2017; and from consulting expenses in 2017, including $220,000 paid by issuing shares of stock to
a consulting firm to assist in sales, placements, company acquisitions, and hiring product distributors; and $42,000 due to an
overpayment of taxes in 2017. Offsets in 2018 were from investor relations, $494,000 due to expenses related to private and public
offerings and from hiring additional analysts and investor relations firms; from an increase in stock based compensation due to
vesting expense for employees, $252,000; increases in legal fees toward merger and acquisition activity, $178,000; increases in
audit and accounting fees due to engaging a new audit firm, $39,000; increases in personnel recruiting fees, $28,000; and payroll,
taxes and benefits, $15,000.
Operations expense.
Operations expense primarily consists
of expenses related to product development and prototyping and testing in the company’s current stage.
Operations expense increased by $196,000 in the three months
ended June 30, 2018 compared to the three months ended June 30, 2017. Increases consisted of $94,000 in stock based compensation
for employee options; $55,000 in research & development; $21,000 in consulting due to TumorGenesis build-up; $15,000 toward
testing for new STREAMWAY parts development; and $6,000 due to increased travel for technical support.
Operations expense increased by $283,000 in the six months ended
June 30, 2018 compared to the six months ended June 30, 2017. Increases consisted of $145,000 in stock based compensation for employee
options; $65,000 in research & development; $27,000 in consulting due to TumorGenesis build-up; $17,000 toward testing for
new STREAMWAY parts development; and, from $27,000 in salary increases for new employees.
Sales and Marketing expense.
Sales and marketing expense
consists of expenses required to sell products through independent reps, attendance at trades shows, product literature and other
sales and marketing activities
.
Sales and marketing expenses increased by $323,000 in the three
months ended June 30, 2018 compared to the three months ended June 30, 2017. The increase in 2018 resulted from $93,000 in salaries,
payroll taxes and benefits for full year to date effect of increased sales staff; $48,000 for stock based compensation for employee
options; $45,000 due to increased commissions due to higher sales in 2018; $45,000 in increased travel to reach more customers;
$38,000 in public relations from hiring a new firm; $19,000 in sales bonuses towards increased sales achievements; $20,000 in market
research from producing strategic market development report; $13,000 for increased trade show attendance; and $10,000 toward new
website development. An offset was for $15,000 in reduced consulting expenses.
Sales and marketing expenses increased by $726,000 in the six
months ended June 30, 2018 compared to the six months ended June 30, 2017. The increase in 2018 resulted from $185,000 in salaries,
payroll taxes and benefits for full year to date effect of increased sales staff; $82,000 for stock based compensation for employee
options; $111,000 due to increased commissions due to higher sales in 2018; $79,000 in increased travel to reach more customers;
$73,000 in public relations from hiring a new firm; $19,000 in sales bonuses towards increased sales achievements; $40,000 in market
research from producing strategic market development report; $16,000 for increased trade show attendance; and $125,000 toward new
website development. An offset was for $11,000 in reduced consulting expenses.
Liquidity and Capital Resources
Cash Flows
Net cash used in operating activities was $3,107,529 for the
six months ended June 30, 2018 compared with net cash used of $2,070,804 for the 2017 period. Cash used increased by $1,037,000
in the 2018 period primarily because the cash used in the 2017 period was partially offset by non-cash expenses relating to vested
options and warrants and equity instruments issued for management and consulting.
Cash flows provided by investing activities was $44,933 for
the six months ended June 30, 2018 and used in investing activities was $2,348,375 for the six months ended June 30, 2017.
The Company redeemed certificates of deposit, which was offset by an increase in notes receivable, fixed assets and intangible
asset purchases.
Net cash provided by financing activities was $3,300,676 for
the six months ended June 30, 2018 compared to net cash provided of $3,814,938 for the six months ended June 30, 2017. The cash
provided came from the net proceeds of the January 2018 public offering and the over-allotment option exercise by the underwriter.
Capital Resources
Our cash and cash equivalents were approximately $1,004,000
as of June 30, 2018. We had a cash balance of $453,000 as of June 30, 2018, with the remainder of our cash equivalents in money
market accounts. Since our inception, we have incurred significant losses. As of June 30, 2018, we had an accumulated deficit of
approximately $58,900,000.
From inception to June 30, 2018, our operations have been funded
through a bank loan and private convertible debt of approximately $5,435,000 and equity investments totaling approximately $35,840,000.
In the first six months of 2018, we recognized $770,000 in revenues.
Plan of Financing; Going Concern Qualification
As a result of the factors below, we believe there is a substantial doubt about the Company’s
ability to continue as a going concern. The financial statements have been prepared assuming the Company will continue as a going
concern.
Since our inception, we have incurred significant losses, and our accumulated deficit
was approximately $58.9 million as of June 30, 2018. Our operations from inception have been funded with private placements of
convertible debt securities and equity securities, in addition to a past bank loan (not currently outstanding) and various public
and private offerings. The Company has raised approximately $35,840,380 in equity offerings, inclusive of (1) $2,055,000 from a
private placement of Series A Convertible Preferred Stock, (2) $13,555,003 from the public offering of Units, (3) $1,739,770 from
a registered direct offering, (4) $3,937,500 plus an overallotment of $358,312 from a firm commitment underwritten public offering,
(5) $1,300,000 from a private placement of Series C Convertible Preferred Stock, (6) $2,755,000 from a firm commitment underwritten
public offering, and (7) $5,685,000 in debt financing.
We have not achieved profitability and anticipate that we will
continue to incur net losses at least for the foreseeable future.
We had revenues of $770,000 in the first six months of 2018,
but we had negative operating cash flows of $3.1 million. The negative cash flow is heavily impacted by our first half loss, which
was largely made up of $761,000 of expenses in investor relations which includes the public offering completed in 2018 and a final
cash payment of approximately $189,000 for conversion of our convertible preferred stock issued in the private placement in November
2017, plus hiring additional investor relations firms; vesting expenses for employee options totaling $460,000, a one-time expense
for $125,000 to develop our new website, and increases in sales and marketing expenses of $726,000 toward expanding our sales
team and global coverage. Our cash balance was $452,838 as of June 30, 2018, with an additional $551,000 in cash equivalents,
and our accounts payable and accrued expenses were an aggregate $621,000. We are currently incurring negative operating cash flows
of approximately $385,000 per month, though the first half operated at a higher rate due to unusual expenses. Although we are
attempting to curtail our expenses, there is no guarantee that we will be able to reduce these expenses significantly, and expenses
for some periods may be higher as we prepare our product for broader sales, increase our sales efforts and maintain adequate inventories.
We will require additional funding to finance our CRO business
and other new business areas, as well as ongoing operating expenses of our STREAMWAY business and investment in our sales organization
and new product development and pursuit of sales in the international marketplace. We have committed significant capital and management
resources to developing our CRO business and other new business areas, and we intend to continue to devote significant management
resources to new businesses. We will incur approximately $70,000 per month in expenses relating to launching the TumorGenesis business.
In addition, in 2017, we provided $668,000 in financing to Helomics, of which $500,000 in principal amount has been converted into
an equity interest in Helomics and $168,000 in principal amount is subject to secured notes that remain outstanding. In addition,
in August 2017, we entered into a merger agreement with CytoBioscience, which was subsequently terminated in November 2017. From
July 2017 through November 2017, we advanced $1,070,000 to CytoBioscience in the form of secured notes, which are still outstanding.
In addition, we have increased our expenditures to develop the business of our TumorGenesis subsidiary, to pursue a new rapid approach
to growing tumors in the laboratory. It is likely that we will make further investments and advances in other businesses as we
develop our CRO business and other business models. Upon completion of the Helomics merger, we expect that our operating cash needs
will increase significantly. There can be no assurance that any of the outstanding balances of our existing promissory notes or
future advances will be repaid. Further, there is no assurance that our equity investment in Helomics or other investments in new
businesses will result in significant value for the Company. Therefore, we could invest significant capital in other business enterprises
with no certainty when or whether we will realize a return on these investments. Investments in cash will deplete our capital resources,
meaning that we will be required to raise significant amounts of new capital. There is no assurance that we will be successful
in raising sufficient capital, and the terms of any such financing will be dilutive to our stockholders. We may also acquire technologies
or companies by issuing stock or other equity securities rather than or in addition to payment of cash, which may have the result
of diluting the investment of our stockholders. Further, the energy and resources of our officers and personnel are being substantially
diverted to these new lines of business, which are unproven. If these businesses are unsuccessful or require too great of a financial
investment to be profitable, our business may fail regardless of the level of success of our STREAMWAY business.
If necessary, we will attempt to raise these funds through equity
or debt financing, alternative offerings or other means. If we are successful in securing adequate funding we plan to make significant
capital or equipment investments, and we will also continue to make human resource additions over the next 12 months. Such additional
financing may be dilutive to existing stockholders, and there is no assurance that such financing will be available upon acceptable
terms. If such financing or adequate funds from operations are not available, we will be forced to limit our business activities,
which will have a material adverse effect on our results of operations and financial condition.
January 2018 Public Offering of Common Stock and Warrants
In January 2018, the Company completed a firm commitment underwritten
public offering of 2,900,000 Units at an offering price of $0.95 per Unit, with each Unit consisting of one share of the Company’s
Common Stock and 0.3 of a Series E Warrant, with each whole Series E Warrant purchasing one share of common stock at an exercise
price of $1.00 per whole share. The shares of Common Stock and Series E Warrants were immediately separable and were issued separately.
Gross proceeds were approximately $2,755,000, before deducting expenses. The Company granted the underwriter a 45-day option to
purchase an additional (i) up to 290,000 additional shares of Common Stock at the public offering price per Unit less the price
of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase
up to 87,000 additional shares of common stock at a purchase price of $0.001 per Series E Warrant to cover over-allotments, if
any. On February 21, 2018, the underwriter exercised on 215,247 shares of common stock, par value $0.01, at $0.9497 per share as
described in the Underwriting Agreement. The Company received net proceeds of $188,066 after deductions of $16,354 representing
the Underwriter’s discount of 8% of the purchase price of the shares.
Off-Balance Sheet Arrangements
We have not engaged in any off-balance sheet activities as defined
in Item 303(a)(4) of Regulation S-K.
Accounting Standards
Revenue Recognition.
Effective January 1,
2018, we adopted Accounting Standards Update (“ASU”)
No.
2014
-
09,
Revenue from
Contracts with Customers (Topic 606),
which outlines a single comprehensive model for entities to use in accounting for
revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when
it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to
be entitled in exchange for those goods or services.
Our product sales consist of a single performance obligation
that the Company satisfies at a point in time. We recognize product revenue when the following events have occurred: (a) the Company
has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal
title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping
terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from
the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, we
determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the
time the products are shipped. We may, at our discretion, negotiate different shipping terms with customers which may affect the
timing of revenue recognition. Standard payment terms for our customers are generally 30 to 60 days after the Company transfers
control of the product to its customer.
Customers may also purchase a maintenance plan from the Company,
which requires that we service the STREAMWAY System for a period of one year subsequent to the one-year anniversary date of the
original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale,
is charged separately from the product sale, and is recognized over time (ratably over the one-year period) as maintenance services
are provided. A time-elapsed output method is used to measure progress because we transfer control evenly by providing a stand-ready
service. We have determined that this method provides a faithful depiction of the transfer of services to our customers.
We record receivables when we have an unconditional right to
receive consideration after the performance obligations are satisfied. As of June 30, 2018, and December 31, 2017, accounts receivable
totaled $315,327 and $137,499, respectively. For the six months ended June 30, 2018, we did not incur material impairment losses
with respect to our receivables.
See “Note 2 – Revenue Recognition,” in Notes
to Financial Statements of this Quarterly Report on Form 10-Q for further discussion.
Stock-Based Compensation
. Effective January 1,
2006, we adopted ASC 718- Compensation-Stock Compensation (“ASC 718”). Under ASC 718 stock-based employee compensation
cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding
at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006,
are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a
straight-line method. We elected the modified-prospective method in adopting ASC 718 under which prior periods are not retroactively
restated.
ASC 718 requires companies to estimate the fair value of stock-based
payment awards on the date of grant using an option-pricing model. We use the Black-Scholes option-pricing model which requires
the input of significant assumptions including an estimate of the average period of time employees and directors will retain vested
stock options before exercising them, the estimated volatility of our common stock price over the expected term, the number of
options that will ultimately be forfeited before completing vesting requirements and the risk-free interest rate.
Because we do not have significant historical trading data on
our common stock we relied upon trading data from a composite of 10 medical companies traded on major exchanges and 15 medical
companies quoted by the OTC Bulletin Board to help us arrive at expectations as to volatility of our own stock when public trading
commences. In the case of options and warrants issued to consultants and investors we used the legal term of the option/warrant
as the estimated term unless there was a compelling reason to use a shorter term. The measurement date for employee and non-employee
options and warrants is the grant date of the option or warrant. The vesting period for options that contain service conditions
is based upon management’s best estimate as to when the applicable service conditions will be achieved. Changes in the assumptions
can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized.
The assumptions we use in calculating the fair value of stock-based payment awards represent our best estimates, which involve
inherent uncertainties and the application of management’s judgment. As a result, if factors change and we use different
assumptions, our equity-based compensation expense could be materially different in the future. See “Note 4 – Stockholders’
Deficit, Stock Options and Warrants” in Notes to Financial Statements of this Quarterly Report on Form 10-Q for additional
information.
When an option or warrant is granted in place of cash compensation
for services, we deem the value of the service rendered to be the value of the option or warrant. In most cases, however,
an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without
utilizing an option pricing model. For that reason we also use the Black-Scholes option-pricing model to value options and
warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period that
investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of our
common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing
vesting requirements and the risk-free interest rate. Changes in the assumptions can materially affect the estimate
of fair value of stock-based compensation and, consequently, the related expense recognizes that. Since we have no trading history
in our common stock and no first-hand experience with how our investors and consultants have acted in similar circumstances, the
assumptions we use in calculating the fair value of stock-based payment awards represent our best estimates, which involve inherent
uncertainties and the application of management's judgment. As a result, if factors change and we use different assumptions,
our equity-based consulting and interest expense could be materially different in the future.
Since our common stock has no significant public trading history
we were required to take an alternative approach to estimating future volatility and the future results could vary significantly
from our estimates. We compiled historical volatilities over a period of 2 to 7 years of 10 small-cap medical companies traded
on major exchanges and 15 medical companies in the middle of the market cap size range on the OTC Bulletin Board and combined the
results using a weighted average approach. In the case of standard options to employees we determined the expected life to
be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees,
we estimated the life to be the legal term unless there was a compelling reason to make it shorter.
Valuation of Intangible Assets
We review identifiable intangible assets for impairment in accordance
with ASC 350-
Intangibles – Goodwill and Other,
whenever events or changes in circumstances indicate the carrying
amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events
or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant
change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such
events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible
asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the
carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered
impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash
flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the
impairment assessment is made. The Company’s enhanced STREAMWAY product has a new patent pending, see “Patents and
Intellectual Property.”
Recent Accounting Developments
See Note 1 - “Summary of Significant Accounting Policies”
to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q for a discussion of recent accounting
developments.
Information Regarding Forward-Looking Statements
This Form 10-Q contains “forward-looking statements”
that indicate certain risks and uncertainties related to the Company, many of which are beyond the Company’s control. The
Company’s actual results could differ materially and adversely from those anticipated in such forward-looking statements
as a result of certain factors, including those set forth below and elsewhere in this report. Important factors that may cause
actual results to differ from projections include:
·
|
Current
negative operating cash flows, including significant investment in our new business areas, past advances to companies with which
we have strategic partnerships and the likelihood of additional such advances, as well as uncertain returns or profitability of
new businesses;
|
·
|
The terms of any further financing, which may be highly dilutive and may include onerous terms;
|
·
|
Risks relating to the proposed merger with Helomics, including uncertainty of completion of the merger, additional expenses relating to the merger and devotion of management resources to the merger;
|
·
|
Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;
|
·
|
The impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology;
|
·
|
Inability to attract or retain qualified senior management personnel, including sales and marketing personnel;
|
·
|
Risk that we never become profitable if our product is not accepted by potential customers;
|
·
|
Possible impact of government regulation and scrutiny;
|
·
|
Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;
|
·
|
Adverse results of any legal proceedings;
|
·
|
The volatility of our operating results and financial condition, and,
|
·
|
Other specific risks that may be alluded to in this report.
|
All statements other than statements of historical facts, included
in this report regarding the Company’s growth strategy, future operations, financial position, estimated revenue or losses,
projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this report, the
words “will”, “may”, “believe”, “anticipate”, “intend”, “estimate”,
“expect”, “project”, “plan” and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only
as of the date of this report. The Company does not undertake any obligation to update any forward-looking statements or other
information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although
the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in
this report are reasonable the Company cannot assure potential investors that these plans, intentions or expectations will be achieved.
The Company discloses important factors that could cause the Company’s actual results to differ materially from its expectations
in the “Risk Factors” section and elsewhere our Annual Report on Form 10-K for the year ended December 31, 2017 and
in item 1A of Part II below. These cautionary statements qualify all forward-looking statements attributable to the Company or
persons acting on its behalf.
Information regarding market and industry statistics contained
in this report is included based on information available to the Company that it believes is accurate. It is generally based on
academic and other publications that are not produced for purposes of securities offerings or economic analysis. The Company has
not reviewed or included data from all sources, and the Company cannot assure potential investors of the accuracy or completeness
of the data included in this report. Forecasts and other forward-looking information obtained from these sources are subject to
the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance
of products and services. The Company has no obligation to update forward-looking information to reflect actual results or changes
in assumptions or other factors that could affect those statements.